YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Tsion Zewdu Minas 1, * , Jenny Han 1, * , Tahereh Javaheri 3 , Sung-Hyeok Hong 1 , Michaela Schlederer 3, 4 , Yasemin Saygideğer-Kont 1 , Haydar Çelik 1 , Kristina M. Mueller 8 , Idil Temel 1 , Metin Özdemirli 2 , Heinrich Kovar 7, 9 , Hayriye Verda Erkizan 1 , Jeffrey Toretsky 1 , Lukas Kenner 3, 4, 5 , Richard Moriggl 3, 6, 8 , Aykut Üren 1 1 Department of Oncology, Georgetown University Medical Center, Washington, DC, USA 2 Department of Pathology, Georgetown University Medical Center, Washington, DC, USA 3 Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria 4 Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria 5 Unit of Pathology of Laboratory Animals, University of Veterinary Medicine, Vienna, Austria 6 Medical University of Vienna, Vienna, Austria 7 Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria 8 Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria 9 Department of Pediatrics, Medical University of Vienna, Vienna, Austria * These authors have contributed equally to this work Correspondence to: Aykut Üren, e-mail: au26@georgetown.edu Keywords: EWS-FLI1, ETS fusion proteins, YK-4-279, ewing sarcoma, erythoid leukemia Received: June 11, 2015 Accepted: September 28, 2015 Published: October 08, 2015 ABSTRACT Ewing sarcoma is an aggressive tumor of bone and soft tissue affecting predominantly children and young adults. Tumor-specific chromosomal translocations create EWS-FLI1 and similar aberrant ETS fusion proteins that drive sarcoma development in patients. ETS family fusion proteins and over-expressed ETS proteins are also found in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Transgenic expression of EWS-FLI1 in mice promotes high penetrance erythroid leukemia with dense hepatic and splenic infiltrations. We identified a small molecule, YK-4-279, that directly binds to EWS-FLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models. Herein, we tested in vivo therapeutic efficacy and potential side effects of YK-4-279 in the transgenic mouse model with EWS-FLI1 induced leukemia. A two-week course of treatment with YK-4-279 significantly reduced white blood cell count, nucleated erythroblasts in the peripheral blood, splenomegaly, and hepatomegaly of erythroleukemic mice. YK-4-279 inhibited EWS-FLI1 target gene expression in neoplastic cells. Treated animals showed significantly better overall survival compared to control mice that rapidly succumbed to leukemia. YK-4-279 treated mice did not show overt toxicity in liver, spleen, or bone marrow. In conclusion, this in vivo study highlights the efficacy of YK-4-279 to treat EWS-FLI1 expressing neoplasms and support its therapeutic potential for patients with Ewing sarcoma and other ETS-driven malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907
Self-citationTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799
The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence.
Karim, F. D., Urness, L. D., Thummel, C. S., Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., Maki, R. A., Gunther, C. V., & Nye, J. A. (1990) · Genes & Development · doi:10.1101/gad.4.9.1451 · Cited by 499 · cited 1×
“com/oncotarget ETS family of transcription factors share a conserved DNA binding domain (ETS domain) all recognizing a purine rich consensus sequence with a central GGAA/T motif [40].”
BackgroundMicrosatellites as EWS/FLI response elements in Ewing's sarcoma
Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801073105 · Cited by 297
TERT promoter mutations in cancer development
Heidenreich, B., Rachakonda, P. S., Hemminki, K., & Kumar, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.005 · Cited by 238
The SH3 Domain of Bruton's Tyrosine Kinase Interacts with Vav, Sam68 and EWS
GUINAMARD, R., FOUGEREAU, M., & SECKINGER, P. (1997) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1997.d01-447.x · Cited by 76
Cited by
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pencik, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Culig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 215
Self-citationTumor target amplification: Implications for nano drug delivery systems
Seidi, K., Neubauer, H. A., Moriggl, R., Jahanban-Esfahlan, R., & Javaheri, T. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.020 · Cited by 145
Self-citationTumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P. (2019) · Cancers · doi:10.3390/cancers11081207 · Cited by 111
“, IL-3) and simultaneous inactivation of SOCS1, the expression of which negatively controls JAK/STAT signaling [114].”
BackgroundSelf-citationCurrent insights into the role of Fli-1 in hematopoiesis and malignant transformation
Ben-David, Y., Gajendran, B., Sample, K. M., & Zacksenhaus, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04160-1 · Cited by 54
Metadata
- Authors
- Minas, T. Z., Han, J., Javaheri, T., Hong, S.-H., Schlederer, M., Saygideğer-Kont, Y., Çelik, H., Mueller, K. M., Temel, I., Özdemirli, M., Kovar, H., Erkizan, H. V., Toretsky, J., Kenner, L., Moriggl, R., & Üren, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-08
- Volume
- 6
- Issue
- 35
- Pages
- 37678-37694
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1828471605
- Cited by
- 23
- References
- 6
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. https://app.cochat.ai/papers/10.18632/oncotarget.5520
- The paper
- Minas, T. Z., Han, J., Javaheri, T., Hong, S.-H., Schlederer, M., Saygideğer-Kont, Y., Çelik, H., Mueller, K. M., Temel, I., Özdemirli, M., Kovar, H., Erkizan, H. V., Toretsky, J., Kenner, L., Moriggl, R., & Üren, A. (2015). YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget. https://doi.org/10.18632/oncotarget.5520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.